Bausch Health Cos Inc. (NYSE:BHC – Free Report) – Equities researchers at Zacks Research cut their Q3 2027 earnings estimates for shares of Bausch Health Cos in a research report issued on Tuesday, May 19th. Zacks Research analyst Team now expects that the company will earn $1.05 per share for the quarter, down from their prior estimate of $1.12. The consensus estimate for Bausch Health Cos’ current full-year earnings is $4.08 per share.
A number of other equities analysts have also commented on BHC. Raymond James Financial reiterated a “market perform” rating on shares of Bausch Health Cos in a report on Monday, January 26th. Royal Bank Of Canada cut their price objective on shares of Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating on the stock in a report on Monday, April 27th. Weiss Ratings lowered shares of Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 4th. Wall Street Zen lowered shares of Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research note on Sunday, February 15th. Finally, Barclays dropped their price objective on shares of Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 25th. Four research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Reduce” and a consensus target price of $8.00.
Bausch Health Cos Stock Performance
Shares of BHC stock opened at $5.51 on Thursday. Bausch Health Cos has a 12 month low of $4.41 and a 12 month high of $8.69. The company has a debt-to-equity ratio of 54.68, a current ratio of 1.32 and a quick ratio of 0.97. The firm has a market capitalization of $2.06 billion, a P/E ratio of -1.70 and a beta of 0.42. The company’s fifty day moving average price is $5.42 and its two-hundred day moving average price is $6.13.
Bausch Health Cos (NYSE:BHC – Get Free Report) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $0.78 EPS for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.03). Bausch Health Cos had a negative return on equity of 2,922.77% and a negative net margin of 11.47%.The firm had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.37 billion.
Insider Activity
In other news, Director Frank D. Lee sold 24,456 shares of the stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $5.43, for a total value of $132,796.08. Following the completion of the transaction, the director directly owned 49,339 shares in the company, valued at $267,910.77. This trade represents a 33.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.67% of the stock is owned by company insiders.
Institutional Trading of Bausch Health Cos
A number of large investors have recently added to or reduced their stakes in BHC. Dynamic Technology Lab Private Ltd bought a new stake in Bausch Health Cos during the first quarter worth approximately $68,000. Jones Financial Companies Lllp boosted its stake in Bausch Health Cos by 1,548.9% in the 1st quarter. Jones Financial Companies Lllp now owns 24,965 shares of the company’s stock worth $162,000 after purchasing an additional 23,451 shares during the period. Goldman Sachs Group Inc. boosted its stake in Bausch Health Cos by 97.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 948,322 shares of the company’s stock worth $6,136,000 after purchasing an additional 467,270 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Bausch Health Cos by 3.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 324,847 shares of the company’s stock worth $2,102,000 after purchasing an additional 9,834 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Bausch Health Cos by 11.2% during the 2nd quarter. Geode Capital Management LLC now owns 840,418 shares of the company’s stock valued at $5,597,000 after buying an additional 84,892 shares during the period. 78.65% of the stock is currently owned by institutional investors.
Key Bausch Health Cos News
Here are the key news stories impacting Bausch Health Cos this week:
- Positive Sentiment: Bausch Health announced results from its 2026 Annual Meeting of Shareholders, saying all 10 director nominees were elected, including new director Eiry W. Roberts, M.D. The vote suggests continued shareholder support and adds a board member with pharmaceutical leadership experience. Bausch Health Announces 2026 Annual Meeting of Shareholder Results
- Positive Sentiment: Zacks Research nudged up its FY2026 EPS estimate for Bausch Health to $3.93 from $3.92, which is a small sign of improving near-term earnings expectations. Zacks Research FY2026 estimate update
- Neutral Sentiment: The company presented at the RBC Capital Markets Global Healthcare Conference and the Barclays Leveraged Finance Conference. These events can help investor visibility, but no major new operating update was provided in the available transcript headlines. RBC Capital Markets Global Healthcare Conference Transcript Barclays Leveraged Finance Conference Transcript
- Neutral Sentiment: Brokerage commentary reported a $8.00 price target, which is supportive but not a direct catalyst on its own. Brokerages Set Bausch Health Cos Inc. Target Price at $8.00
- Negative Sentiment: Zacks Research trimmed several longer-term earnings forecasts for Bausch Health, including FY2027, FY2028, Q2 2027, Q3 2026, and Q1 2028, signaling softer growth expectations farther out. Zacks Research earnings estimate changes
- Negative Sentiment: Director Frank D. Lee sold 24,456 shares in a pre-arranged Rule 10b5-1 transaction. While routine, insider selling can still weigh on sentiment for BHC. SEC Form 4 insider sale filing
Bausch Health Cos Company Profile
Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.
The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.
See Also
- Five stocks we like better than Bausch Health Cos
- From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
- AI Consolidation Begins: Blackstone & Google Forge an AI Empire
- USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms
- 3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO
Receive News & Ratings for Bausch Health Cos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Cos and related companies with MarketBeat.com's FREE daily email newsletter.
